SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Learn more about:
Related Clinical Trial
Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Tazemetostat in Malignant Peripheral Nerve Sheath Tumors
A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1
SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
Vaccine Therapy in Treating Patients With Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery
Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)
A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery
Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors